文献速递精神分裂症与精神病性障碍物质与行为成瘾

大麻成分所致精神症状:系统综述与荟萃分析

Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2020-03-17

该系统综述与荟萃分析纳入15项THC急性给药研究和4项CBD联合THC研究,发现健康人单次使用THC后总症状、阳性症状和阴性症状严重程度均显著增加且效应量大;CBD是否缓解THC所致症状证据不一致。

要点

  • 健康人单次使用THC可急性诱发精神病性、阴性及其他精神症状,效应量大。
  • THC显著增加BPRS/PANSS总症状、阳性症状和阴性症状严重度,均p<0·0001。
  • 4项CBD联合THC研究中仅1项报告症状显著减轻,CBD调节作用证据不一致。

核心结论

  • 单次THC给药可在健康人中诱发精神病性、阴性及其他精神症状,效应量大。
  • 无一致证据表明CBD本身诱发症状或调节THC所致症状。
  • 研究结果提示含THC的大麻及其他大麻素用于娱乐或治疗目的时存在潜在风险。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和PsycINFO至2019年5月21日的英文研究。
  • 纳入标准为健康受试者急性静脉、口服或鼻用THC、CBD及安慰剂后以BPRS和PANSS评估症状的自身对照交叉设计研究。
  • 共纳入15项THC急性给药研究和4项CBD联合THC给药研究。
  • 采用随机效应荟萃分析评估THC与安慰剂相比对PANSS和BPRS总分、阳性分和阴性分效应量的影响。
  • CBD调节作用因研究数量不足仅作系统综述,方案注册号PROSPERO CRD42019136674。

主要发现

  • 与安慰剂相比,THC显著增加总症状严重度(9项研究、10个独立样本、196名受试者:SMC 1·10 [95% CI 0·92-1·28],p<0·0001)。
  • THC显著增加阳性症状严重度(14项研究、15个独立样本、324名受试者:SMC 0·91 [95% CI 0·68-1·14],p<0·0001)。
  • THC显著增加阴性症状严重度且效应量大(12项研究、13个独立样本、267名受试者:SMC 0·78 [95% CI 0·59-0·97],p<0·0001)。
  • 系统综述中4项评估CBD对THC所致症状影响的研究仅1项发现症状显著减轻。

关键数值与推荐

  • THC vs 安慰剂总症状SMC 1·10(95% CI 0·92-1·28),p<0·0001,基于9项研究10个独立样本196名受试者。
  • THC vs 安慰剂阳性症状SMC 0·91(95% CI 0·68-1·14),p<0·0001,基于14项研究15个独立样本324名受试者。
  • THC vs 安慰剂阴性症状SMC 0·78(95% CI 0·59-0·97),p<0·0001,基于12项研究13个独立样本267名受试者。
  • CBD对THC所致症状的调节作用因研究数量不足未做荟萃分析,仅系统综述4项研究,其中1项报告症状显著减轻。

临床怎么用

  • 临床评估使用大麻者出现精神病性、阴性或抑郁焦虑症状时,应考虑THC急性诱发症状的可能。
  • 对含THC的大麻素用于娱乐或治疗目的时应告知其急性精神症状风险。
  • 不能依据现有证据认为CBD可稳定缓解THC所致精神症状。

局限性

  • CBD调节THC所致症状的研究数量不足,无法进行荟萃分析,仅作系统综述。
  • 纳入研究为健康受试者急性给药交叉设计,结果外推至长期使用者或患者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 188 million people use cannabis yearly worldwide, and it has recently been legalised in 11 US states, Canada, and Uruguay for recreational use. The potential for increased cannabis use highlights the need to better understand its risks, including the acute induction of psychotic and other psychiatric symptoms. We aimed to investigate the effect of the cannabis constituent Δ9-tetrahydrocannabinol (THC) alone and in combination with cannabidiol (CBD) compared with placebo on psychiatric symptoms in healthy people. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, and PsycINFO for studies published in English between database inception and May 21, 2019, with a within-person, crossover design. Inclusion criteria were studies reporting symptoms using psychiatric scales (the Brief Psychiatric Rating Scale [BPRS] and the Positive and Negative Syndrome Scale [PANSS]) following the acute administration of intravenous, oral, or nasal THC, CBD, and placebo in healthy participants, and presenting data that allowed calculation of standardised mean change (SMC) scores for positive (including delusions and hallucinations), negative (such as blunted affect and amotivation), and general (including depression and anxiety) symptoms. We did a random-effects meta-analysis to assess the main outcomes of the effect sizes for total, positive, and negative PANSS and BPRS scores measured in healthy participants following THC administration versus placebo. Because the number of studies to do a meta-analysis on CBD's moderating effects was insufficient, this outcome was only systematically reviewed. This study is registered with PROSPERO, CRD42019136674. FINDINGS: 15 eligible studies involving the acute administration of THC and four studies on CBD plus THC administration were identified. Compared with placebo, THC significantly increased total symptom severity with a large effect size (assessed in nine studies, with ten independent samples, involving 196 participants: SMC 1·10 [95% CI 0·92-1·28], p<0·0001); positive symptom severity (assessed in 14 studies, with 15 independent samples, involving 324 participants: SMC 0·91 [95% CI 0·68-1·14], p<0·0001); and negative symptom severity with a large effect size (assessed in 12 studies, with 13 independent samples, involving 267 participants: SMC 0·78 [95% CI 0·59-0·97], p<0·0001). In the systematic review, of the four studies evaluating CBD's effects on THC-induced symptoms, only one identified a significant reduction in symptoms. INTERPRETATION: A single THC administration induces psychotic, negative, and other psychiatric symptoms with large effect sizes. There is no consistent evidence that CBD induces symptoms or moderates the effects of THC. These findings highlight the potential risks associated with the use of cannabis and other cannabinoids that contain THC for recreational or therapeutic purposes. FUNDING: UK Medical Research Council, Maudsley Charity, Brain and Behavior Research Foundation, Wellcome Trust, and the UK National Institute for Health Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020. PMID: 32197092. doi:10.1016/S2215-0366(20)30074-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。